Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

ß3 integrin modulates transforming growth factor beta induced (TGFBI) function and paclitaxel response in ovarian cancer cells.

Tumbarello DA, Temple J, Brenton JD.

Mol Cancer. 2012 May 28;11:36. doi: 10.1186/1476-4598-11-36.

2.

SPARC Regulates Transforming Growth Factor Beta Induced (TGFBI) Extracellular Matrix Deposition and Paclitaxel Response in Ovarian Cancer Cells.

Tumbarello DA, Andrews MR, Brenton JD.

PLoS One. 2016 Sep 13;11(9):e0162698. doi: 10.1371/journal.pone.0162698. eCollection 2016.

3.

The extracellular matrix protein TGFBI induces microtubule stabilization and sensitizes ovarian cancers to paclitaxel.

Ahmed AA, Mills AD, Ibrahim AE, Temple J, Blenkiron C, Vias M, Massie CE, Iyer NG, McGeoch A, Crawford R, Nicke B, Downward J, Swanton C, Bell SD, Earl HM, Laskey RA, Caldas C, Brenton JD.

Cancer Cell. 2007 Dec;12(6):514-27.

4.

Dexamethasone enhances cell resistance to chemotherapy by increasing adhesion to extracellular matrix in human ovarian cancer cells.

Chen YX, Wang Y, Fu CC, Diao F, Song LN, Li ZB, Yang R, Lu J.

Endocr Relat Cancer. 2010 Jan 29;17(1):39-50. doi: 10.1677/ERC-08-0296. Print 2010 Mar.

5.

TGFBI promoter hypermethylation correlating with paclitaxel chemoresistance in ovarian cancer.

Wang N, Zhang H, Yao Q, Wang Y, Dai S, Yang X.

J Exp Clin Cancer Res. 2012 Jan 16;31:6. doi: 10.1186/1756-9966-31-6.

6.

Transforming growth factor beta-induced (TGFBI) is an anti-adhesive protein regulating the invasive growth of melanoma cells.

Nummela P, Lammi J, Soikkeli J, Saksela O, Laakkonen P, Hölttä E.

Am J Pathol. 2012 Apr;180(4):1663-74. doi: 10.1016/j.ajpath.2011.12.035. Epub 2012 Feb 9.

PMID:
22326753
7.

Multiple FAS1 domains and the RGD motif of TGFBI act cooperatively to bind αvβ3 integrin, leading to anti-angiogenic and anti-tumor effects.

Son HN, Nam JO, Kim S, Kim IS.

Biochim Biophys Acta. 2013 Oct;1833(10):2378-88. doi: 10.1016/j.bbamcr.2013.06.012. Epub 2013 Jun 19.

8.

Oncostatin M promotes mesenchymal stem cell-stimulated tumor growth through a paracrine mechanism involving periostin and TGFBI.

Lee MJ, Heo SC, Shin SH, Kwon YW, Do EK, Suh DS, Yoon MS, Kim JH.

Int J Biochem Cell Biol. 2013 Aug;45(8):1869-77. doi: 10.1016/j.biocel.2013.05.027. Epub 2013 Jun 2.

PMID:
23735324
9.

Transforming growth Factor-Beta-Induced Protein (TGFBI)/(βig-H3): a matrix protein with dual functions in ovarian cancer.

Ween MP, Oehler MK, Ricciardelli C.

Int J Mol Sci. 2012;13(8):10461-77. doi: 10.3390/ijms130810461. Epub 2012 Aug 21. Review.

10.

Combined expression of KLK4, KLK5, KLK6, and KLK7 by ovarian cancer cells leads to decreased adhesion and paclitaxel-induced chemoresistance.

Loessner D, Quent VM, Kraemer J, Weber EC, Hutmacher DW, Magdolen V, Clements JA.

Gynecol Oncol. 2012 Dec;127(3):569-78. doi: 10.1016/j.ygyno.2012.09.001. Epub 2012 Sep 8.

PMID:
22964375
11.

Transforming growth factor-β-induced protein (TGFBI) suppresses mesothelioma progression through the Akt/mTOR pathway.

Wen G, Hong M, Li B, Liao W, Cheng SK, Hu B, Calaf GM, Lu P, Partridge MA, Tong J, Hei TK.

Int J Oncol. 2011 Oct;39(4):1001-9. doi: 10.3892/ijo.2011.1097. Epub 2011 Jun 23.

12.

POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer.

Karlan BY, Dering J, Walsh C, Orsulic S, Lester J, Anderson LA, Ginther CL, Fejzo M, Slamon D.

Gynecol Oncol. 2014 Feb;132(2):334-42. doi: 10.1016/j.ygyno.2013.12.021. Epub 2013 Dec 22.

PMID:
24368280
13.

Silencing dishevelled-1 sensitizes paclitaxel-resistant human ovarian cancer cells via AKT/GSK-3β/β-catenin signalling.

Zhang K, Song H, Yang P, Dai X, Li Y, Wang L, Du J, Pan K, Zhang T.

Cell Prolif. 2015 Apr;48(2):249-58. doi: 10.1111/cpr.12161. Epub 2015 Jan 21.

PMID:
25643607
14.

TGFBI expression is associated with a better response to chemotherapy in NSCLC.

Irigoyen M, Pajares MJ, Agorreta J, Ponz-Sarvisé M, Salvo E, Lozano MD, Pío R, Gil-Bazo I, Rouzaut A.

Mol Cancer. 2010 May 28;9:130. doi: 10.1186/1476-4598-9-130.

15.

Akt involvement in paclitaxel chemoresistance of human ovarian cancer cells.

Kim SH, Juhnn YS, Song YS.

Ann N Y Acad Sci. 2007 Jan;1095:82-9.

PMID:
17404021
16.

The thyroid hormone-αvβ3 integrin axis in ovarian cancer: regulation of gene transcription and MAPK-dependent proliferation.

Shinderman-Maman E, Cohen K, Weingarten C, Nabriski D, Twito O, Baraf L, Hercbergs A, Davis PJ, Werner H, Ellis M, Ashur-Fabian O.

Oncogene. 2016 Apr 14;35(15):1977-87. doi: 10.1038/onc.2015.262. Epub 2015 Jul 13.

PMID:
26165836
17.

TGFbeta-induced protein mediates lymphatic endothelial cell adhesion to the extracellular matrix under low oxygen conditions.

Irigoyen M, Ansó E, Salvo E, Dotor de las Herrerías J, Martínez-Irujo JJ, Rouzaut A.

Cell Mol Life Sci. 2008 Jul;65(14):2244-55. doi: 10.1007/s00018-008-8071-9.

PMID:
18560760
18.

TGF-β-induced (TGFBI) protein in melanoma: a signature of high metastatic potential.

Lauden L, Siewiera J, Boukouaci W, Ramgolam K, Mourah S, Lebbe C, Charron D, Aoudjit F, Jabrane-Ferrat N, Al-Daccak R.

J Invest Dermatol. 2014 Jun;134(6):1675-1685. doi: 10.1038/jid.2014.20. Epub 2014 Jan 17.

19.
20.

Tectorigenin sensitizes paclitaxel-resistant human ovarian cancer cells through downregulation of the Akt and NFκB pathway.

Yang YI, Lee KT, Park HJ, Kim TJ, Choi YS, Shih IeM, Choi JH.

Carcinogenesis. 2012 Dec;33(12):2488-98. doi: 10.1093/carcin/bgs302. Epub 2012 Oct 1.

PMID:
23027625

Supplemental Content

Support Center